Abstract
Postpartum hemorrhage
(PPH) remains one of the leading causes of maternal morbidity and mortality
worldwide, particularly in low- and middle-income countries. This article
critically reviews pharmacological, mechanical and organizational prophylactic
interventions aimed at reducing the incidence and severity of PPH. The
administration of uterotonics, particularly oxytocin and misoprostol, combined
with active management of the third stage of labor and the use of intrauterine
tamponade devices, has shown effectiveness in immediate hemostasis and
reduction of long-term complications. Standardized institutional protocols and
obstetric emergency training are essential to optimize early recognition and
rapid treatment of PPH, significantly improving clinical outcomes and maternal
safety.
Keywords: Postpartum hemorrhage; Prophylaxis; Uterotonics;
Active management; Intrauterine devices
Introduction
Postpartum hemorrhage (PPH) is defined as blood loss equal to
or greater than 500 mL within the first 24 hours after vaginal delivery or
1,000 mL after cesarean section1,2. It is considered an obstetric emergency due to the risk of
hypovolemic shock, disseminated intravascular coagulation and maternal death3. PPH accounts for
approximately 27% of maternal deaths in developing countries and occurs in up
to 10% of deliveries worldwide4. Risk factors include labor dystocia, uterine rupture,
placenta previa or low-lying placenta, placenta accreta, preeclampsia,
gestational anemia, prolonged oxytocin use during labor and a history of
previous PPH. The high prevalence and severe consequences of this event have
driven the continuous search for evidence-based prophylactic strategies. From a
pharmacological standpoint, the administration of intra- or intravenous
uterotonics immediately after fetal expulsion is the mainstay of prophylaxis.
Oxytocin is the first-line agent, recommended as a single
dose of 10 IU intramuscularly or a continuous infusion of 20–40 IU in 1000 mL
of 0.9% saline for up to 4 hours, reducing the incidence of significant PPH by
up to 60% and decreasing the need for blood transfusions by 40%. In
resource-limited settings where oxytocin stability may be compromised by the
lack of a cold chain, misoprostol, a prostaglandin E1 analog, offers logistical
advantages. Studies show that 600 µg of sublingual misoprostol reduces the risk
of PPH by up to 50%, although it is associated with a higher frequency of
thermal and gastrointestinal adverse effects, such as transient fever and
nausea. Other pharmacological options, such as ergometrine (0.2 mg
intramuscularly) and carboprost tromethamine (250 µg intramuscularly)5, are indicated as
alternatives or adjunct therapies, especially in patients with
contraindications to oxytocin or in refractory cases.
Ergometrine has shown similar efficacy to oxytocin but with a
higher incidence of arterial hypertension and headache. Carboprost shows 70-80%
efficacy in secondary PPH prophylaxis and is reserved for first-line agent
failure scenarios.
In addition to pharmacological interventions, active
management of the third stage of labor including delayed cord clamping,
controlled cord traction and immediate uterine massage enhances uterine
contractions and facilitates placental separation, reducing average blood loss
by up to 30%. Active inspection of the uterus and cervix, along with bimanual
uterine massage, enables early detection of atony and immediate application of
direct hemostatic techniques. In cases of refractory bleeding, intrauterine tamponade
devices such as the Bakri balloon offer effective mechanical tamponade, with
hemostatic success rates exceeding 85% and potential to avoid invasive surgical
procedures such as arterial embolization or emergency hysterectomy.
Transcervical insertion and gradual balloon inflation with saline provide
direct compression on the placental bed, rapidly reducing bleeding6.
On na organizational level, the implementation of
standardized institutional protocols combined with simulated obstetric
emergency training has demonstrated a 20–30% reduction in response time to PPH
diagnosis and significant decrease in management variability. These strategies
include emergency checklists, clear role definitions within ontexto plinar
teams and ontexto communication flows between obstetricians, anesthesiologists,
nurses and blood banks. Given the complexity of prophylactic management, each obstetric
unit must tailor recommendations to its local ontexto, ensuring systematic
monitoring of clinical indicators and periodic process reviews. The combination
of pharmacological, mechanical and organizational approaches forms the
foundation for sustainable PPH reduction and improved maternal safety7,8.
Objectives
Materials and Methods
A literature
review was conducted using the databases PubMed, SciELO, Google Scholar and
ScienceDirect.
Discussion
Several randomized clinical
trials have demonstrated the superiority of oxytocin over placebo and other
interventions, with an average reduction in blood loss of 150-200 mL and an
odds ratio of 0.35 for severe PPH. Direct comparison between oxytocin and
ergometrine showed similar efficacy but distinct safety profiles9. Ergometrine had a higher
incidence of hypertension and cardiovascular adverse reactions, whereas
oxytocin had few side effects when administered according to protocol10. The logistical resistance to
using refrigerated oxytocin prompted studies on misoprostol, which proved to be
a viable alternative in remote regions, with up to 50% efficacy in reducing severe
PPH. However, variability in dose and route of administration oral, sublingual
or rectal requires standardization and training to minimize adverse events.
The Bakri balloon and similar
devices have emerged as second-line interventions for refractory PPH, with
reported success rates between 85–95%. These technologies require specific
training for proper insertion and recognition of complications, such as uterine
perforation or balloon displacement. Systematic application of active
management, including uterine massage and controlled cord traction, has been
shown to reduce the duration of the third stage and average blood loss,
contributing to reduced incidence of mild to moderate PPH. Visual and tactile
inspection of the uterus after placental expulsion allows for early
intervention in cases of atony11.
Adapted protocols and
high-fidelity simulation training have a direct hock on reducing the time
between diagnosis and intervention, resulting in improved clinical outcomes12-14. Brazilian studies reported a
30% decrease in the rate of emergency hysterectomies and hypovolemic hock
following the implementation of training programs. Prophylaxis with oxytocin
and standardized protocols has been shown to reduce hospital costs by up to 25%
by minimizing prolonged hospital stays and the need for transfusions. These
findings support the importance of investment in medication stockpiles and
continuous training15.
Conclusion
Postpartum hemorrhage represents
one of the greatest challenges in modern obstetrics, especially in settings
where access to timely and effective interventions is limited. Literature
analysis shows that pharmacological prophylaxis, particularly with oxytocin, is
the most robust pillar in preventing PPH, significantly reducing blood loss and
the need for transfusions. Alternatives such as misoprostol are valuable in
settings with deficient infrastructure, although they have a more pronounced
adverse effect profile. The association of agents like ergometrine and
carboprost in refractory cases adds value to the therapeutic arsenal, although
their use must be carefully weighed against cardiovascular risks. Active
management of the third stage of labor emerges as an essential and low-cost
practice that significantly contributes to the prevention of hemorrhagic
complications. Controlled cord traction, immediate uterine massage and
post-placental uterine inspection have a positive impact on hemostasis,
reinforcing the importance of training obstetric teams for proper execution. In
refractory bleeding situations, the use of intrauterine tamponade devices, such
as the Bakri balloon, is a safe and effective intervention, capable of
preventing more invasive surgical procedures and reducing associated morbidity
and mortality. At the same time, the organizational component of health
institutions plays a decisive role in the quality of response to hemorrhagic
emergencies.
The implementation of
standardized clinical protocols, combined with realistic simulation training
and integrated team communication, reduces the time between diagnosis and
intervention, improves clinical decision-making and promotes better maternal
outcomes. Standardizing practices and continuous professional development are,
therefore, essential measures to reduce disparities in care and ensure safe
obstetric management. It is concluded that effective prevention of PPH requires
a multifaceted approach adapted to local realities, combining high-efficacy
pharmacological resources, evidence-based obstetric techniques and
well-structured organizational systems. Investing in professional training,
continuous availability of essential medications and well-structured care
protocols is essential to reduce maternal mortality and achieve consistent
progress in global obstetric health. Tackling PPH, therefore, is not limited to
adopting isolated measures but involves consolidating an institutional culture
of safety and excellence in maternal care.
References
2. Brasil. Ministério da Saúde. Atenção
humanizada ao parto e nascimento. Portaria n.º 3.716. Diário Oficial da União
2014.
3. Dodd JM, Grivell
RM. Uterine massage for preventing postpartum haemorrhage. Cochrane Database
Syst Rev 2011;(7):006431.
4. Elder MG, Rowe
RC. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage
following cesarean section. Cochrane Database Syst Rev 2010;(3):005457.
5. Fuselier M, Novitsky
T, Goldberg AB. Use of intrauterine balloons in the management of refractory
postpartum hemorrhage. Obstet Gynecol 2019;133(2):314-320.
6. Hall MC, Stam
D, Cowan D. Comparison of misoprostol and oxytocin for prevention of postpartum
hemorrhage in low-resource settings. BJOG 2015;122(5):682-691.
7. Karim R, Hussain
A. Cost-effectiveness of uterotonic prophylaxis in preventing postpartum
hemorrhage: a systematic review. Health Econ Rev 2017;7(1):20.
8. Lee CW, Lee
HH. Efficacy of active management of the third stage of labor. Int J Obstet
Anesth 2014;23(1):13-19.
9. Moraes MC, Silva
JL. Impacto do treinamento em emergência obstétrica na redução de hemorragia
pós-parto. Rev Saúde Pública 2018;52:65.
10. Mavrides D, Allen
S, Choudhari Y, et al. Prevention and management of postpartum haemorrhage. Int
J Gynaecol Obstet 2016;133(4):217-233.
11. Pritchard
JA. Postpartum hemorrhage: management and prevention. Obstet Gynecol Clin North
Am 2011;38(2):271-292.
12. Sentilhes L,
Tachet A, Chevalier S, et al. Postpartum haemorrhage: prevention and treatment.
Nat Rev Dis Primers 2016;2:16035.
13. Smith J, Barnard
K. Balloon tamponade in the management of postpartum hemorrhage: multi-center
study. Am J Obstet Gynecol 2020;223(6):903.e1-903.e5.
14. Torres M, Almeida
C. Profilaxia farmacológica da hemorragia pós-parto: revisão de diretrizes. Rev
Bras Ginecol Obstet 2018;40(8):435-443.
15. World Health Organization. WHO
recommendations for the prevention and treatment of postpartum haemorrhage.
Geneva: WHO 2012.